Rigel
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
611 Gateway Blvd Ste 900, South San Fran...Phone Number
(650) 624-1100Website
www.rigel.comRevenue
$299.8 MillionStock Symbol
RIGLIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Rigel
Founded in 1996, Rigel Pharmaceuticals is a drug development company that specializes in the discovery and development of small-molecule drugs for the treatment of autoimmune diseases, muscle disorders and inflammatory diseases. Rigel Pharmaceuticals is headquartered in San Francisco, California.Explore more
Rigel Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rigel your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Rigel recently announced quarterly report
Click to see if Rigel had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Rigel has new funding data
Check if Rigel has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Rigel launches new products
Rigel, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Rigel is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Rigel
Recommended Actions
Find VP level buyers at Rigel
Find 3 more new buyers
Compare Similar Companies to Rigel
Compare insights from companies similar to Rigel, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Rigel is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Rigel is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Rigel.
Rigel financials insights
Gather financial insights about Rigel, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Stock Offering
$127.5M
2009
Stock Offering
$101.5M
2011
Stock Offering
$140.5M
2012
Stock Offering
$135.7M
2017
Stock Offering
$46M
Stock Offering
$69.7M
2018
Stock Offering
$58.4M
2019
Debt
$60M
Rigel Tech Stack
A closer look at the technologies used by Rigel
Most Recent Scoops
Hiring Plans
Rigel Pharmaceuticals has more open roles in Information Technology than it has had at any time in the past 12 months.
Hiring Plans
Partnership
Partnership, Product Management, Business Development, Intellectual Property, Legal Affairs, Pharmaceuticals
Partnership
Rigel Pharmaceuticals has partnered with Knight Therapeutics to sell TAVALISSE in Latin America, where the product has been approved and launched in Mexico and approved in Brazil.
Project
Rigel Pharmaceuticals has highlighted a market opportunity of well over $1 billion for vepdegestrant (Bepanu), targeting approximately 47,000 ESR1-mutant metastatic breast cancer patients in the US, with diagnosis rates continuing to increase.
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
Rigel News & Media
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 She has resigned from Rigel's Board of Directors to join the company SOUTH SAN FRANCISCO, Calif., July 1, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL),...Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the...Rigel to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview...Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLC Final analysis from the Phase 1/2 ARROW clinical trial of pralsetinib in patients with...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rigel
Sign Up For FreeTo access detailed company insights
Founded in 1996, Rigel Pharmaceuticals is a drug development company that specializes in the discovery and development of small-molecule drugs for the treatment of autoimmune diseases, muscle disorders and inflammatory diseases. Rigel Pharmaceuticals is headquartered in San Francisco, California.... Read More
